Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Ophthalmology

Articles with lock require a GLG News subscription
Posted January 3, 2007
ANOTHER ocular allergy drop? What is ISTA thinking?
Analysis of: ISTA Pharmaceuticals Submits Investigational New Drug Application For Eye Drop For The Treatment Of Allergic Conjunctivitis | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Apparently, with only about a dozen other topical ophthalmic allergy medications available in the US, ISTA has decided that the market can bear one more: bepotastine. However, with the imminent release of Alcon's PATADAY - the first once-daily allergy eye drop - and Alimera / B&L's ALAWAY - the...
Posted January 3, 2007
Triple therapy for allergic conjunctivitis
Analysis of: ISTA Pharmaceuticals Submits Investigational New Drug Application For Eye Drop For The Treatment Of Allergic Conjunctivitis | www.medicalnewstoday.com
Author: GLG Member Program Contributor
This drug may have an edge over its competition due to its unique mechanism of action.
Posted January 3, 2007
Putting the cart before the horse.
Analysis of: ISTA Pharmaceuticals Submits Investigational New Drug Application For Eye Drop For The Treatment Of Allergic Conjunctivitis | www.medicalnewstoday.com
Author: GLG Member Program Contributor
A IND has been filed. This means an Investigational New Drug (IND), it does not mean NDA a new drug application. Comments on this drug should be treated with great speculation both positive and negative because it really is too early to make a final conclusion.
Posted December 29, 2006
AMP, not sorbitol, appears to be the issue with Systane Free
Analysis of: Alcon Announces Voluntary Recall of Systane® Free LIQUID GEL Lubricant Eye Drops in the United States | www.fda.gov
Author: GLG Member Program Contributor
According to sources at Alcon, the preservation system in Travatan Z (SofZia) is not susceptible to mold growth, as compared to that of Systane Free.
Posted December 22, 2006
Artisan Phakic Intraocular Lens: limited market Appeal (No Threat to LASIK)
Analysis of: Functional Outcome and Patient Satisfaction After Artisan Phakic Intraocular Lens Implantation for the Correction of Myopia | www.ajo.com
Author: GLG Member Program Contributor
Despite short term patient satisfaction for the correction of myopia, with the multiple problems and issues associated with the approval of the Visian ICL (phakic iol) for correction of myopia over the past several years, and some studies that indicated higher corneal endothelial cell count loss and...
Posted December 22, 2006
AVASTIN WILL NOT GO AWAY (Wet Macular Degeneration Therapy)
Analysis of: Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration. | www.ajo.com
Author: GLG Member Program Contributor
While the authors caution that further studies are required to evaluate the safety and efficacy of Avastin, it is clear that there is a huge interest in this therapy for macular degenration due to its apparent effectivity and relative low cost in relation to other similar anti vgef therapies. ...
Posted December 22, 2006
Intravitreal Triamcinolone Effective in Diabetic Macular Swelling
Analysis of: Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. | www.ncbi.nlm.nih.gov
Author: GLG Member Program Contributor
This study shows that other NON-anti VGEF medicines continue to have a role in treating macular swelling and will not likely be completely abandoned in favor of the more expensive options now available.  Given its likely affectivity as an adjunct or possible replacement for many patients, and its...
Posted December 18, 2006
Laser Vision Correction will continue to be popular.
Analysis of: Laser Eye Surgery May Be Harmful to Long-Term Vision | www.newsinferno.com
Author: GLG Member Program Contributor
Health advisories will have a minimal impact on the number of patients willing to go under laser. Moreover, data suggests more patients will opt for this elective procedure.
Posted December 18, 2006
Yet Another Recall in the Ophthalmic Market: Systane Free
Analysis of: Alcon Announces Voluntary Recall of Systane® Free LIQUID GEL Lubricant Eye Drops in the United States | www.fda.gov
Author: GLG Member Program Contributor
This represents the third recall in 2006 of a major ophthalmic product related to microbial contamination. Bausch and Lomb has been the most hard-hit, with numerous associated cases of Fusarium keratitis. Advance Medical Ophthalmics (Complete Moisture Plus) and Alcon (Systane Free) stand to fare better,...
Posted December 18, 2006
Systane Free Recall Does Not Impact Travatan Z
Analysis of: Alcon Announces Voluntary Recall of Systane® Free LIQUID GEL Lubricant Eye Drops in the United States | www.fda.gov
Author: GLG Member Program Contributor
Travatan Z is a newly released glaucoma medication, incorporating the prostaglandin analog travoprost and a unique, proprietary preservation system called SofZia. SofZia incorporates many of the same elements as the preservation system for Systane Free, which was recently the subject of a nationwide...
Previous Page : 11 12 13 14 15 16 17 18 19 20 21 22 Next201 to 210 of 220

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-11-21T13:45:47.600